Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Material Agreement (May 7, 2025)

Reports
Leadership Changes·Material Agreements·Regulation FD+1
Filing Date
Filed May 7, 2025
Period End
May 7, 2025
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.

On May 6, 2025, Charles River Laboratories International, Inc. entered into a Cooperation Agreement with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P.

(the Elliott Parties), effective that date. Under the agreement, the company will appoint Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves to its Board of Directors effective following the 2025 Annual Meeting, each with a term expiring at the 2026 Annual Meeting. Four incumbent directors, Robert Bertolini, Deborah T.

Kochevar, George E. Massaro and Richard F. Wallman, will not stand for re-election at the 2025 Annual Meeting, which is scheduled for May 20, 2025.

The company also agreed to appoint at least one Investor Designated Director to the Strategic Partnership and Capital Allocation Committee, the Compensation Committee and the Corporate Governance and Nominating Committee, and to limit the Board to no more than 11 members until the Cooperation Period expires. The Board, through the Strategic Committee, will conduct a comprehensive review and evaluation of the company's business and prospects, including an examination of various alternatives to enhance long-term stockholder value. The Cooperation Agreement includes voting commitments, customary standstill restrictions and mutual non-disparagement provisions.

The Cooperation Period runs until the later of 30 calendar days before the advance notice deadline for 2026 Annual Meeting nominations and the day an Investor Director ceases to serve on the Board. The company's press release states that Elliott is its largest investor and that the Board will have eleven directors, nine of whom will be independent. The press release also states that Elliott's partner said the company's current value is significantly disconnected from its underlying potential.

Items 5.02(d) and 1.01 describe committee assignments and a non-employee director initial equity award valued at $255,500a before pro-rata adjustment, split 50% restricted stock or units and 50% stock options. The filing is signed by Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer.

Key Highlights

  1. Cooperation Agreement with Elliott Investment Management L.P. and affiliated Elliott Parties, dated May 6, 2025, filed as Exhibit 10.1
  2. Four new directors to join the Board after the May 20, 2025 Annual Meeting: Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves, each with a term expiring at the 2026 Annual Meeting
  3. Four incumbent directors, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman, will not stand for re-election at the 2025 Annual Meeting
  4. Board to conduct a comprehensive strategic review, through the Strategic Committee, of the company's business and alternatives to enhance long-term stockholder value
  5. Board size capped at no more than 11 members until the Cooperation Period expires; the press release states nine of eleven directors will be independent
  6. Cooperation Agreement includes voting commitments, customary standstill restrictions and mutual non-disparagement provisions
  7. Non-employee directors appointed after the 2025 Annual Meeting receive an initial equity award with a value of $255,500 before pro-rata adjustment

Frequently Asked Questions

  1. Who is Elliott Investment Management and what role does it play?

    The filing identifies Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. as the Elliott Parties to the Cooperation Agreement. The press release describes Elliott as Charles River's largest investor.

  2. When will the new directors join the Board?

    The Board has agreed to elect the Cooperation Agreement Directors as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, effective immediately following that election, with terms expiring at the 2026 Annual Meeting.

  3. What is the scope of the strategic review?

    The Board, through the Strategic Committee, will conduct a comprehensive review and evaluation of the company's business and prospects, including an examination of various alternatives to enhance long-term stockholder value. The press release states the committee will present its recommendations to the full Board upon completion of its review.

  4. How long do the Cooperation Agreement's restrictions last?

    The voting commitments, customary standstill restrictions and mutual non-disparagement provisions remain in place until the later of 30 calendar days before the advance notice deadline for non-proxy access director nominations for the 2026 Annual Meeting and the first day an Investor Director ceases to serve on the Board.

  5. Who will chair the Board's committees after these changes?

    The press release states that Martin Mackay, Ph.D. will serve as Lead Independent Director, Nancy Andrews, M.D., Ph.D. will chair the Corporate Governance and Nominating Committee, Reshema Kemps-Polanco will chair the Compensation Committee, Virginia Wilson will remain Audit Committee Chair, and Paul Graves will chair the Strategic Planning and Capital Allocation Committee.